CADE proposes remedy for GSK/Pfizer

Andrew Putwain

01 May 2019

CADE proposes remedy for GSK/Pfizer

Credit: iStock/William Barton

The investigative arm of Brazil’s competition authority has raised concerns that GlaxoSmithKline’s pending acquisition of Pfizer’s consumer healthcare division could lead to higher prices for simple antacids.